←Back to Expert Scholars
Translational Medicine / 转化医学MDS, Hypomethylating Agents
Lewis Silverman
MD
🏢Icahn School of Medicine at Mount Sinai🌐USA
Professor of Medicine, Hematology and Medical Oncology
65
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Lewis Silverman is a pioneer of hypomethylating agent therapy for MDS at Mount Sinai and led pivotal CALGB trials establishing azacitidine as standard therapy. He has contributed to understanding mechanisms and optimal use of azacitidine. His work has defined modern MDS drug therapy.
Share:
🧪Research Fields 研究领域
azacitidine MDS
hypomethylating agents
MDS clinical trials
CALGB MDS trials
myelodysplastic syndromes
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Lewis Silverman 的研究动态
Follow Lewis Silverman's research updates
留下邮箱，当我们发布与 Lewis Silverman（Icahn School of Medicine at Mount Sinai）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment